Dr. Reddy's Laboratories publishes notice on unclaimed dividend transfer

Dr. Reddy's Laboratories Ltd has informed the stock exchanges about the transfer of unclaimed dividends and underlying equity shares to the Investor Education and Protection Fund (IEPF). The company published a notice in this regard on May 27, 2026, in newspapers Business Standard and Nava Telangana. This transfer is being carried out pursuant to Section 124(6) of the Companies Act, 2013, and the rules thereunder.

The disclosure was submitted to the National Stock Exchange of India Ltd and BSE Limited. The notice serves to inform shareholders and ensure compliance with regulatory requirements regarding unclaimed corporate benefits.

Details of the Disclosure

The company provided specific details regarding the publication and the regulatory framework governing the transfer of funds.

Parameter	Details
Subject	Transfer of unclaimed dividend and equity shares to IEPF
Publication Date	May 27, 2026
Newspapers	Business Standard, Nava Telangana
Regulatory Section	Section 124(6) of the Companies Act, 2013

The filing was signed by K Randhir Singh, Company Secretary, Compliance Officer & Head-CSR of Dr. Reddy's Laboratories Limited. The document was digitally signed on May 27, 2026.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.18%	-1.39%	-2.32%	+4.34%	+4.85%	+23.70%

Dr. Reddy's Laboratories Limited has confirmed full compliance with the Securities and Exchange Board of India (SEBI) regulations for the financial year ended March 31, 2026. The annual secretarial audit, conducted by M/s. Makarand M. Joshi & Co., Practicing Company Secretaries, verified the company's adherence to the SEBI Act, 1992, the Securities Contracts (Regulation) Act, 1956, and various associated regulations including the Listing Obligations and Disclosure Requirements Regulations, 2015.

The certification process examined the company's documents, records, filings with stock exchanges, and its website. The report confirms that the listed entity complied with all provisions of the reviewed regulations and circulars during the review period. There were no deviations reported, and no fines were imposed.

Compliance Status

The audit assessed the company's adherence to specific governance and operational standards. The following table summarizes the compliance status for key areas:

Sr. No.	Particulars	Compliance Status
1.	Compliance with Secretarial Standards issued by ICSI	Yes
2.	Adoption and timely updation of policies under SEBI Regulations	Yes
3.	Maintenance and disclosures on Website	Yes
4.	Disqualification of Director under Section 164 of Companies Act, 2013	Yes
5.	Identification and disclosure of material subsidiary companies	Yes
6.	Preservation of Documents as per SEBI Regulations	Yes
7.	Performance Evaluation of Board and Committees	Yes
8.	Related Party Transactions (RPT) prior approval	Yes
9.	Disclosure of events or information under Regulation 30	Yes
10.	Prohibition of Insider Trading Regulations, 2015	Yes

Regulatory Actions and Observations

The report explicitly states that no actions were taken against the listed entity, its promoters, directors, or subsidiaries by SEBI or the Stock Exchanges during the review period. Additionally, there were no resignations of statutory auditors from the company or its material subsidiaries, and no additional non-compliances were observed.

The audit also noted that the company had complied with SEBI Circular no SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, regarding the disclosure of Employee Benefit Scheme documents. The report, signed by Partner Makarand M. Joshi, assumes the responsibility of management for the authenticity of documents and clarifies that the certification is neither an audit nor an expression of opinion on the financial records.